Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07753603 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study to Assess Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED)

Study acronym: ORBIT
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Secondary endpoints: details revised at 1 of 4 entriesv2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to evaluate the efficacy, safety, and tolerability of linsitinib in participants with moderate to severe Thyroid Eye Disease (TED).
Trial Details
NCT Number NCT07753603
Lead Sponsor Sling Therapeutics, Inc.
Conditions
(from sponsor)		 Thyroid Eye Disease, TED, Graves Orbitopathy
Related terms Graves Disease, Graves Ophthalmopathy, Hashimoto Disease
Enrollment 130 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov